CAJ | 학술논문

肺动脉高压(PAH)是以血管阻塞和血管收缩为特征,呈进行性发展,并最终导致持续性肺动脉阻力增加和右心衰竭的一种疾病.PAH分为原发性和继发性两大类型,其发病机制至今尚不非常明确,基本病理改变有三个方面:肺血管收缩、血管重塑、原位血栓的形成.许多动物实验证实他汀类药物可能通过抑制细胞增殖、诱导细胞凋亡、抑制炎症反应、抗氧化等多种作用预防和缓解PAH.因此基于疾病的发病机制和药物的多效性,他汀类药物已经被认为是治疗PAH的一种有利选择.现对他汀类药物在PAH治疗中的研究现况进行综述,并探讨其可能作用机制,为他汀类药物在PAH的治疗中提供理论依据.
폐동맥고압(PAH)시이혈관조새화혈관수축위특정,정진행성발전,병최종도치지속성폐동맥조력증가화우심쇠갈적일충질병.PAH분위원발성화계발성량대류형,기발병궤제지금상불비상명학,기본병리개변유삼개방면:폐혈관수축、혈관중소、원위혈전적형성.허다동물실험증실타정류약물가능통과억제세포증식、유도세포조망、억제염증반응、항양화등다충작용예방화완해PAH.인차기우질병적발병궤제화약물적다효성,타정류약물이경피인위시치료PAH적일충유리선택.현대타정류약물재PAH치료중적연구현황진행종술,병탐토기가능작용궤제,위타정류약물재PAH적치료중제공이론의거.
Pulmonary arterial hypertension (PAH) is a progressive and often fatal disease characterized by vascular obstruction and vasoconstriction,leading to persistent elevation of pulmonary arterial resistance and right-sided heart failure.PAH is classified into primary and secondary forms.Its pathogenesis is still not very clear,but the basic pathological alteration of pulmonary hypertension contains three dependent elements:pulmonary vasoconstriction,pulmonary vascular remodeling and pulmonary microvascular thrombogenesis.Statins have been shown to both prevent and attenuate pulmonary hypertension in animal models and this was associated with increased apoptosis and reduced proliferation of smooth muscle cells,inhibit inflammation response,anti-oxidation and so on.Therefore,statins have been considered as a therapeutic option in PAH based on the pathogenesis of the disease and the pleiotropic actions that these agents exert.The researches using statins to treat pulmonary hypertension were reviewed and the possible mechanisms were postulated.They provide a theoretical basis for statins in the treatment of pulmonary hypertension.